Positive Phase 3 data should drive near-term stock appreciation. Monitor regulatory decisions in Q3 2026 and commercial launch preparations. The collaboration with Sino Biopharmaceutical in China is a key catalyst for ex-US upside.
Price Chart
Executive Summary
GSK announced positive pivotal Phase 3 data for bepirovirsen, achieving a 19% functional cure rate in chronic hepatitis B (vs 0% placebo), with a 26% rate in patients with lower viral activity. The drug is under priority review by the FDA, with first regulatory decisions expected in Q3 2026. This represents a potential first-in-class treatment for a large unmet need, positioning GSK for significant revenue upside if approved.
Key Facts
- Bepirovirsen achieved 19% functional cure rate (233/1220) vs 0% placebo in overall population (p<0.001)
- 26% functional cure rate (200/768) in patients with baseline HBsAg ≤1000 IU/mL (p<0.001)
- 49% of bepirovirsen recipients achieved qHBsAg ≤100 IU/mL one year after treatment
- First regulatory decisions anticipated in Q3 2026 from FDA (priority review with Breakthrough and Fast Track designations)
- GSK entered strategic collaboration with Sino Biopharmaceutical to accelerate access in China
- Over 240 million people worldwide live with chronic hepatitis B
Financial Impact
Potential multi-billion dollar revenue opportunity if approved, given large addressable patient population and first-in-class profile; no financial terms disclosed
Risk Factors
- Regulatory delay or requirement for additional trials
- Competition from other HBV treatments in development
- Safety profile concerns, though current data shows acceptable tolerability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005453 |
| Document: 0001654954-26-005453-index-headers.html | 0001654954-26-005453 |
| Document: 0001654954-26-005453-index.html | 0001654954-26-005453 |
| Document: 0001654954-26-005453.txt | 0001654954-26-005453 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers